Description and Consequences of Prescribing Off-Label Antiretrovirals in the Madrid Cohort of HIV-Infected Children over a Quarter of a Century (1988–2012)
Free accessAnnouncementFirst published online January, 2016
Description and Consequences of Prescribing Off-Label Antiretrovirals in the Madrid Cohort of HIV-Infected Children over a Quarter of a Century (1988–2012)
Licensing data for paediatric dosing is often sparse and subsequent studies may result in changes to recommended doses. We measured the extent and consequences of off-label antiretroviral (ARV) use in an HIV-infected paediatric cohort.
Methods
In this multicentre cohort study involving 318 HIV-infected children and adolescents from the Madrid Cohort, all off-label prescriptions from March 1988 to March 2012 were recorded from the clinical records. The reasons for prescribing ARV off-label, the side effects and the consequences of incorrect dosing of ARVs are discussed.
Results
Among the 318 patients of the cohort, 221 (69%) received off-label ARVs according to EMA licensing at the time of prescription, representing 23% (540) of the 2,353 prescribed ARVs. The main reason for starting an off-label drug was treatment failure. Adverse events led to treatment discontinuation in 12% of the prescriptions. Problems taking the drug led to withdrawal in 5%, more likely when formulation was not suitable for age (P<0.05). Up to 10% were overdosed and 10% underdosed, defined as 25% above or below the current recommended dose, respectively. Treatment failure occurred significantly more frequently among underdosed compared to overdosed patients (50% versus 26%; P<0.05).
Conclusions
Off-label use of ARVs was common in our HIV-1 paediatric patients. Adverse events were common but rarely led to withdrawal. Suitable formulation is important in younger children. Pharmacokinetic studies are needed as frequent incorrect dosing may occur when prescribing off-label and underdosing may lead to treatment failure.
MensonE.N., WalkerA.S., SharlandM.Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort study.BMJ2006; 332: 1183–1187.
3.
ConroyS., ChoonaraI., ImpicciatoreP.Survey of unlicensed and off label drug use in paediatric wards in European countries.BMJ2000; 320: 79–82.
BazzanoA.T., Mangione-SmithR., SchonlauM., SuttorpM.J., BrookR.H.Off-label prescribing to children in the United States outpatient setting.Acad Pediatr2009; 9: 81–88.
6.
SchirmE., TobiH., de Jong- van den BergL.T.Risk factors for unlicensed and off-label drug use in children outside the hospital.Pediatrics2003; 111: 291–295.
7.
GulickR.M., LalezariJ., GoodrichJ.Maraviroc for previously treated patients with R5 HIV-1 infection.N Engl J Med2008; 359: 1429–1441.
8.
PENTA Steering Committee, WelchS., SharlandM.PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.HIV Med2009; 10: 591–613.
AiroldiM., ZaccarelliM., BisiL.One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects.Patient Prefer Adherence2010; 4: 115–125.
11.
CossariniF., SalpietroS., GalliL.Monotherapy with atazanavir as a simplification strategy: results from an observational study.J Acquir Immune Defic Syndr2012; 60: e101–e103.
12.
LuzuriagaK., BrysonY., McSherryG.Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.J Infect Dis1996; 174: 713–721.
13.
FraaijP.L., VerweelG., van RossumA.M., HartwigN.G., BurgerD.M., de GrootR.Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.Infection2007; 35: 186–189.
14.
GiacometV., MoraS., MartelliL., MerloM., SciannambloM., ViganòA.A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.J Acquir Immune Defic Syndr2005; 40: 448–450.
15.
GafniR.I., HazraR., ReynoldsJ.C.Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.Pediatrics2006; 118: e711–e718.
16.
AurpibulL., PuthanakitT.Review of tenofovir use in HIV-infected children.Pediatr Infect Dis J2015; 34: 383–391.
17.
GibbD.M., GoodallR.L., GiacometV., McGeeL., CompagnucciA., LyallH.Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.Pediatr Infect Dis J2003; 22: 56–62.
18.
BurgerD.M., BergshoeffA.S., De GrootR.Maintaining the nelfinavir trough concentration above 0.8 mg/l improves virologic response in HIV-1-infected children.J Pediatr2004; 145: 403–405.
